ImmunityBio stockholders approve 2025 Equity Incentive Plan, re-elect directors

ImmunityBio, Inc.

2025 Equity Incentive Plan approved; reserves 46,088,027 new shares plus up to 32,359,674 from expired/forfeited 2015 Plan awards.
All eight director nominees re-elected at June 18, 2025 annual meeting; 89% of shares represented.
Deloitte & Touche ratified as independent auditor for fiscal 2025 with 99.5% votes in favor.
Plan replaces 2015 Plan; no further awards under prior plan, but existing grants continue.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.